I. Executive Summary Background The 5 years since the publication of the first International
Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed …

Topical glucocorticoids are a well-known risk factor of intraocular pressure (IOP) elevation in
one third of the general population and in up to 90% of glaucomatous patients. Whether this …

Chronic rhinosinusitis (CRS) is a chronic inflammatory condition affecting the nasal and
paranasal sinuses of approximately 11.5% of the United States adult population. Oral …

Introduction Allergic fungal rhinosinusitis (AFRS) is a chronic disorder with significant
morbidity and a high recurrence rate needing long-term follow-up. Even after its first …

Chronic rhinosinusitis is an upper respiratory disease during which topical drug treatment
via the nasal cavity is the most actively utilized therapeutic strategy. In addition to steroids …

Abstract Purpose of Review Intranasal corticosteroid sprays have been available as over-the-
counter (OTC) medications since 2013. As such, clinicians need to be up-to-date with the …

Objectives To address concerns related to the safety profile of both Food and Drug
Administration (FDA)–approved and non–FDA-approved intranasal corticosteroid (INCS) …

Introduction: Chronic rhinosinusitis is a common condition characterized by inflammation of
the nasal and sinus linings, rhinorrhea, nasal blockage, facial pain, and loss of sense of …

Objective: The purpose of this scholarly review is to present an update of the efficacy, safety,
and distribution of intranasal corticosteroids (INCS) in the context of treatment for chronic …

Background Intranasal corticosteroids (INCS) are used in the management of sinonasal
conditions. Use of exogenous steroids can be associated with hypothalamic‐pituitary …